Physician profile
Nathan Hamblin
NPI 1891123550
$7,206.88
in general payments reported to CMS, 2019-2025
28 companies · $2,530 in 2025
The $2,530 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $312 · 2022: $917 · 2023: $1,782 · 2024: $1,667 · 2025: $2,530.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,812 · Education: $167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,811.59 |
| Education | $166.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,011.98 | 2021-2025 | |
| Genzyme Corporation | $677.42 | 2022-2025 | |
| Ucb, INC. | $613.95 | 2021-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $573.23 | 2022-2025 | Taltz, Ebglyss, Olumiant |
| Janssen Biotech, INC. | $535.67 | 2021-2025 | Tremfya |
| Incyte Corporation | $430.36 | 2023-2025 | Opzelura |
| Amgen INC. | $414.26 | 2022-2025 | Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $401.82 | 2023-2025 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $359.92 | 2022-2025 | |
| Pfizer INC. | $350.29 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $301.37 | 2021-2025 | Dupixent |
| Journey Medical Corporation | $289.50 | 2021-2025 | |
| Galderma Laboratories, L.P. | $224.48 | 2024-2025 | Nemluvio |
| Leo Pharma INC. | $134.75 | 2022-2025 | Anzupgo, Adbry |
| Janssen Scientific Affairs, LLC | $122.83 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $120.47 | 2025 | Vtama, Nexplanon |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $109.98 | 2022-2024 | Siliq, Duobrii |
| Sanofi-Aventis U.S. LLC | $99.99 | 2023 | |
| Arcutis Biotherapeutics, INC. | $96.38 | 2023-2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $88.22 | 2021-2024 | Ilumya |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.28 | 2024-2025 | Spevigo |
| Krystal Biotech INC | $51.26 | 2024 | Vyjuvek |
| Dermavant Sciences, INC. | $42.56 | 2023-2024 | Vtama |
| Verrica Pharmaceuticals INC. | $32.45 | 2024-2025 | Ycanth |
| Vyne Pharmaceuticals INC. | $20.15 | 2021 | |
| Biofrontera INC. | $19.26 | 2023-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Organogenesis INC. | $16.98 | 2024 | |
| Helsinn Therapeutics (U.S.), INC. | $15.07 | 2023 | Valchlor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Hamblin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.